Pooling placebo-controlled RCTs of subcutaneous semaglutide in adults with NAFLD/NASH, this meta-analysis quantifies the GLP-1 receptor agonist's liver-specific impact: a 114% increase in NASH resolution without fibrosis progression (RR = 2.14, 95% CI 1.44–3.17), a meaningful AST reduction of 6.72 U/L, nearly 7% body weight loss, and a striking 1.29% HbA1c improvement. Critically, fibrosis stage improvement fell short of significance (RR = 1.14, p = .67), the finding that most limits enthusiasm for semaglutide as a standalone liver-disease modifier.
The fibrosis null result is the pivotal tension here. NASH resolution matters clinically, but advanced fibrosis — not lobular inflammation — is the strongest predictor of liver-related mortality. Resmetirom, approved by the FDA in 2024 for MASH with fibrosis, demonstrated statistically significant fibrosis regression in the MAESTRO-NASH trial, setting a bar semaglutide has not yet cleared in head-to-head histologic terms. The metabolic benefits semaglutide delivers — weight reduction and glycemic control — are themselves hepatoprotective over time, suggesting combination regimens pairing a GLP-1 agonist with a thyroid hormone receptor-β agonist or FXR agonist may ultimately prove superior.
Limitations are meaningful: trial numbers and follow-up durations remain short for a fibrosis endpoint that evolves over years, and GI-driven dropout could bias histologic responder pools. This meta-analysis is confirmatory and clinically useful rather than paradigm-shifting, solidifying semaglutide's role in metabolic optimization for MASH patients while underscoring that fibrosis reversal requires additional therapeutic strategies.